This report aims to provide a comprehensive presentation of the global market for Non-Insulin Therapies for Diabetes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Therapies for Diabetes. This report contains market size and forecasts of Non-Insulin Therapies for Diabetes in global, including the following market information:
Global Non-Insulin Therapies for Diabetes Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Insulin Therapies for Diabetes market was valued at US$ 32870 million in 2022 and is projected to reach US$ 58240 million by 2030, at a CAGR of 8.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Alpha-glucosidase Inhibitors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-Insulin Therapies for Diabetes include GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Insulin Therapies for Diabetes companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Insulin Therapies for Diabetes Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Type, 2022 (%)
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Global Non-Insulin Therapies for Diabetes Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Application, 2022 (%)
Monitoring
Diagnosis
Treatment
Others
Global Non-Insulin Therapies for Diabetes Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Insulin Therapies for Diabetes revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Insulin Therapies for Diabetes revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Insulin Therapies for Diabetes, market overview.
Chapter 2: Global Non-Insulin Therapies for Diabetes market size in revenue.
Chapter 3: Detailed analysis of Non-Insulin Therapies for Diabetes company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Insulin Therapies for Diabetes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Insulin Therapies for Diabetes Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Insulin Therapies for Diabetes Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Insulin Therapies for Diabetes Overall Market Size
2.1 Global Non-Insulin Therapies for Diabetes Market Size: 2022 VS 2030
2.2 Global Non-Insulin Therapies for Diabetes Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Insulin Therapies for Diabetes Players in Global Market
3.2 Top Global Non-Insulin Therapies for Diabetes Companies Ranked by Revenue
3.3 Global Non-Insulin Therapies for Diabetes Revenue by Companies
3.4 Top 3 and Top 5 Non-Insulin Therapies for Diabetes Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Insulin Therapies for Diabetes Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Players in Global Market
3.6.1 List of Global Tier 1 Non-Insulin Therapies for Diabetes Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Insulin Therapies for Diabetes Market Size Markets, 2022 & 2030
4.1.2 Alpha-glucosidase Inhibitors
4.1.3 Amylin Agonists
4.1.4 Biguanides
4.1.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
4.1.6 Glinides / Meglitinides
4.1.7 GLP-1 Analogs / GLP-1 Agonists
4.1.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
4.1.9 Sulfonylureas
4.1.10 Thiazolidinediones
4.1.11 Others
4.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
4.2.1 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2018-2023
4.2.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2024-2030
4.2.3 By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Insulin Therapies for Diabetes Market Size, 2022 & 2030
5.1.2 Monitoring
5.1.3 Diagnosis
5.1.4 Treatment
5.1.5 Others
5.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
5.2.1 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2018-2023
5.2.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2024-2030
5.2.3 By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Insulin Therapies for Diabetes Market Size, 2022 & 2030
6.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
6.2.1 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2018-2023
6.2.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2024-2030
6.2.3 By Region - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Insulin Therapies for Diabetes Revenue, 2018-2030
6.3.2 US Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.3.3 Canada Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.3.4 Mexico Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Insulin Therapies for Diabetes Revenue, 2018-2030
6.4.2 Germany Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.3 France Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.4 U.K. Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.5 Italy Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.6 Russia Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.7 Nordic Countries Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.4.8 Benelux Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Insulin Therapies for Diabetes Revenue, 2018-2030
6.5.2 China Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.5.3 Japan Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.5.4 South Korea Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.5.5 Southeast Asia Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.5.6 India Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Insulin Therapies for Diabetes Revenue, 2018-2030
6.6.2 Brazil Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.6.3 Argentina Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, 2018-2030
6.7.2 Turkey Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.7.3 Israel Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Insulin Therapies for Diabetes Market Size, 2018-2030
6.7.5 UAE Non-Insulin Therapies for Diabetes Market Size, 2018-2030
7 Non-Insulin Therapies for Diabetes Companies Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Non-Insulin Therapies for Diabetes Major Product Offerings
7.1.4 GSK Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Major Product Offerings
7.2.4 Eli Lilly Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Sumitomo Dainippon Pharma
7.3.1 Sumitomo Dainippon Pharma Company Summary
7.3.2 Sumitomo Dainippon Pharma Business Overview
7.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Major Product Offerings
7.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.3.5 Sumitomo Dainippon Pharma Key News & Latest Developments
7.4 Intarcia Therapeutics
7.4.1 Intarcia Therapeutics Company Summary
7.4.2 Intarcia Therapeutics Business Overview
7.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Major Product Offerings
7.4.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.4.5 Intarcia Therapeutics Key News & Latest Developments
7.5 Servier
7.5.1 Servier Company Summary
7.5.2 Servier Business Overview
7.5.3 Servier Non-Insulin Therapies for Diabetes Major Product Offerings
7.5.4 Servier Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.5.5 Servier Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-Insulin Therapies for Diabetes Major Product Offerings
7.6.4 Pfizer Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Non-Insulin Therapies for Diabetes Major Product Offerings
7.7.4 Merck Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.7.5 Merck Key News & Latest Developments
7.8 Dong-A Pharmaceutical
7.8.1 Dong-A Pharmaceutical Company Summary
7.8.2 Dong-A Pharmaceutical Business Overview
7.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.8.4 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.8.5 Dong-A Pharmaceutical Key News & Latest Developments
7.9 Luye Pharma Group
7.9.1 Luye Pharma Group Company Summary
7.9.2 Luye Pharma Group Business Overview
7.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.9.4 Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.9.5 Luye Pharma Group Key News & Latest Developments
7.10 Eurofarma
7.10.1 Eurofarma Company Summary
7.10.2 Eurofarma Business Overview
7.10.3 Eurofarma Non-Insulin Therapies for Diabetes Major Product Offerings
7.10.4 Eurofarma Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.10.5 Eurofarma Key News & Latest Developments
7.11 Geropharm
7.11.1 Geropharm Company Summary
7.11.2 Geropharm Business Overview
7.11.3 Geropharm Non-Insulin Therapies for Diabetes Major Product Offerings
7.11.4 Geropharm Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.11.5 Geropharm Key News & Latest Developments
7.12 Alkem Labs
7.12.1 Alkem Labs Company Summary
7.12.2 Alkem Labs Business Overview
7.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Major Product Offerings
7.12.4 Alkem Labs Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.12.5 Alkem Labs Key News & Latest Developments
7.13 SatRx
7.13.1 SatRx Company Summary
7.13.2 SatRx Business Overview
7.13.3 SatRx Non-Insulin Therapies for Diabetes Major Product Offerings
7.13.4 SatRx Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.13.5 SatRx Key News & Latest Developments
7.14 Jiangsu Hansoh Pharmaceutical
7.14.1 Jiangsu Hansoh Pharmaceutical Company Summary
7.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
7.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.14.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.14.5 Jiangsu Hansoh Pharmaceutical Key News & Latest Developments
7.15 Novo Nordisk
7.15.1 Novo Nordisk Company Summary
7.15.2 Novo Nordisk Business Overview
7.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Major Product Offerings
7.15.4 Novo Nordisk Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.15.5 Novo Nordisk Key News & Latest Developments
7.16 Emisphere
7.16.1 Emisphere Company Summary
7.16.2 Emisphere Business Overview
7.16.3 Emisphere Non-Insulin Therapies for Diabetes Major Product Offerings
7.16.4 Emisphere Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.16.5 Emisphere Key News & Latest Developments
7.17 Uni-Bio Science Group
7.17.1 Uni-Bio Science Group Company Summary
7.17.2 Uni-Bio Science Group Business Overview
7.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.17.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.17.5 Uni-Bio Science Group Key News & Latest Developments
7.18 Takeda
7.18.1 Takeda Company Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Non-Insulin Therapies for Diabetes Major Product Offerings
7.18.4 Takeda Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.18.5 Takeda Key News & Latest Developments
7.19 3SBio
7.19.1 3SBio Company Summary
7.19.2 3SBio Business Overview
7.19.3 3SBio Non-Insulin Therapies for Diabetes Major Product Offerings
7.19.4 3SBio Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.19.5 3SBio Key News & Latest Developments
7.20 Jiangsu Hengrui Medicine
7.20.1 Jiangsu Hengrui Medicine Company Summary
7.20.2 Jiangsu Hengrui Medicine Business Overview
7.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Major Product Offerings
7.20.4 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue in Global Market (2018-2023)
7.20.5 Jiangsu Hengrui Medicine Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Insulin Therapies for Diabetes Market Opportunities & Trends in Global Market
Table 2. Non-Insulin Therapies for Diabetes Market Drivers in Global Market
Table 3. Non-Insulin Therapies for Diabetes Market Restraints in Global Market
Table 4. Key Players of Non-Insulin Therapies for Diabetes in Global Market
Table 5. Top Non-Insulin Therapies for Diabetes Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Insulin Therapies for Diabetes Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Insulin Therapies for Diabetes Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Insulin Therapies for Diabetes Product Type
Table 9. List of Global Tier 1 Non-Insulin Therapies for Diabetes Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Insulin Therapies for Diabetes Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Insulin Therapies for Diabetes Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2024-2030
Table 30. GSK Company Summary
Table 31. GSK Non-Insulin Therapies for Diabetes Product Offerings
Table 32. GSK Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 33. GSK Key News & Latest Developments
Table 34. Eli Lilly Company Summary
Table 35. Eli Lilly Non-Insulin Therapies for Diabetes Product Offerings
Table 36. Eli Lilly Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly Key News & Latest Developments
Table 38. Sumitomo Dainippon Pharma Company Summary
Table 39. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Offerings
Table 40. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 41. Sumitomo Dainippon Pharma Key News & Latest Developments
Table 42. Intarcia Therapeutics Company Summary
Table 43. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Offerings
Table 44. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 45. Intarcia Therapeutics Key News & Latest Developments
Table 46. Servier Company Summary
Table 47. Servier Non-Insulin Therapies for Diabetes Product Offerings
Table 48. Servier Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 49. Servier Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Non-Insulin Therapies for Diabetes Product Offerings
Table 52. Pfizer Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Non-Insulin Therapies for Diabetes Product Offerings
Table 56. Merck Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 57. Merck Key News & Latest Developments
Table 58. Dong-A Pharmaceutical Company Summary
Table 59. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Offerings
Table 60. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 61. Dong-A Pharmaceutical Key News & Latest Developments
Table 62. Luye Pharma Group Company Summary
Table 63. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Offerings
Table 64. Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 65. Luye Pharma Group Key News & Latest Developments
Table 66. Eurofarma Company Summary
Table 67. Eurofarma Non-Insulin Therapies for Diabetes Product Offerings
Table 68. Eurofarma Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 69. Eurofarma Key News & Latest Developments
Table 70. Geropharm Company Summary
Table 71. Geropharm Non-Insulin Therapies for Diabetes Product Offerings
Table 72. Geropharm Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 73. Geropharm Key News & Latest Developments
Table 74. Alkem Labs Company Summary
Table 75. Alkem Labs Non-Insulin Therapies for Diabetes Product Offerings
Table 76. Alkem Labs Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 77. Alkem Labs Key News & Latest Developments
Table 78. SatRx Company Summary
Table 79. SatRx Non-Insulin Therapies for Diabetes Product Offerings
Table 80. SatRx Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 81. SatRx Key News & Latest Developments
Table 82. Jiangsu Hansoh Pharmaceutical Company Summary
Table 83. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Offerings
Table 84. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 85. Jiangsu Hansoh Pharmaceutical Key News & Latest Developments
Table 86. Novo Nordisk Company Summary
Table 87. Novo Nordisk Non-Insulin Therapies for Diabetes Product Offerings
Table 88. Novo Nordisk Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 89. Novo Nordisk Key News & Latest Developments
Table 90. Emisphere Company Summary
Table 91. Emisphere Non-Insulin Therapies for Diabetes Product Offerings
Table 92. Emisphere Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 93. Emisphere Key News & Latest Developments
Table 94. Uni-Bio Science Group Company Summary
Table 95. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Offerings
Table 96. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 97. Uni-Bio Science Group Key News & Latest Developments
Table 98. Takeda Company Summary
Table 99. Takeda Non-Insulin Therapies for Diabetes Product Offerings
Table 100. Takeda Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 101. Takeda Key News & Latest Developments
Table 102. 3SBio Company Summary
Table 103. 3SBio Non-Insulin Therapies for Diabetes Product Offerings
Table 104. 3SBio Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 105. 3SBio Key News & Latest Developments
Table 106. Jiangsu Hengrui Medicine Company Summary
Table 107. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Offerings
Table 108. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue (US$, Mn) & (2018-2023)
Table 109. Jiangsu Hengrui Medicine Key News & Latest Developments
List of Figures
Figure 1. Non-Insulin Therapies for Diabetes Segment by Type in 2022
Figure 2. Non-Insulin Therapies for Diabetes Segment by Application in 2022
Figure 3. Global Non-Insulin Therapies for Diabetes Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Insulin Therapies for Diabetes Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Insulin Therapies for Diabetes Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2022
Figure 8. By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 16. US Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 20. Germany Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 28. China Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 34. Brazil Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue Market Share, 2018-2030
Figure 37. Turkey Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2018-2030
Figure 41. GSK Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Servier Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pfizer Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eurofarma Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Geropharm Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Alkem Labs Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. SatRx Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Novo Nordisk Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Emisphere Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Takeda Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. 3SBio Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
